Clinical Trials Browser

INDUSTRY × TH 302 × Clear all

NCT00742963 2025-05-13

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

Phase 1/2 Completed

107 enrolled 7 charts

Sarcoma

NCT01746979 2025-05-11

MAESTRO

Phase 3 Completed

693 enrolled 8 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT01864538 2025-05-11

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Phase 2 Terminated

11 enrolled 8 charts

Melanoma, Neoplasm Metastasis

NCT02047500 2025-05-11

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Phase 1 Terminated

19 enrolled 6 charts

Gastrointestinal

Pancreatic Neoplasms

NCT06782555 2025-01-21

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

Phase 1/2 Recruiting

GastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Pancreatic Neoplasms, Prostatic Neoplasms

NCT02255110 2018-12-14

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Phase 2 Terminated

6 enrolled 6 charts

Sarcoma

NCT01833546 2018-10-15

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Phase 1 Completed

20 enrolled 35 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Phase 1 Unknown

DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01440088 2016-06-02

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Phase 3 Completed

Sarcoma

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT02020226 2016-06-02

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Phase 1 Unknown

Other solid neoplasm

Solid Tumors

NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Phase 1/2 Completed

GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01149915 2015-05-07

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01381822 2014-04-21

TH-CR-410

Phase 1 Unknown

GastrointestinalSarcoma

Neuroectodermal Tumors, Primitive, Gastrointestinal Stromal Tumors

NCT00495144 2012-07-27

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Phase 1 Completed

Hypoxia, Neoplasms